News Hub | News Direct

K3 Holdings and Alpine LA Properties Congratulate Team USA for Winning Paris Olympics Medal Count

K3 Holdings

K3 Holdings, a privately held real estate investment firm with extensive holdings throughout the United States and Alpine LA Properties, a leasing company providing newly remodeled apartments at affordable rates in Los Angeles, congratulated Team USA for their outstanding performance in the Paris Olympics. Following more than two weeks of competition and lifetimes of preparation, athletes representing the United States won 126 medals (40 gold) leading all other countries at the conclusion of the games in Paris. "Congratulations to Team USA for showcasing the true spirit of excellence and determination, bringing home the most medals and making us all proud,” stated Michael Kadisha, a Principal of K3 Holdings. "Winning the most medals is a triumph of skill and perseverance, and more so, a testament to the unity and resilience that define the American spirit. Dedication, hard work, and a never-give-up attitude leads to greatness, and we are all inspired by the performance of our athletes in Paris.” "In sports, as in life, the way we handle victory says as much about us as the victory itself. Gratitude and humility elevate every achievement. Winning with grace and losing with dignity are the hallmarks of true champions,” Michael Kadisha continued. “The K3 Holdings and Alpine teams were impressed at how Team USA proved themselves to be real winners by celebrating their victories while honoring their opponents with respect and gratitude.” The Olympics serve as a unique platform where nations from every corner of the globe come together in a spirit of friendly competition. Beyond the medals and records, the Olympics foster an environment where cultural exchange and mutual understanding thrive. In a world often divided by differences, the Olympics create a space where adversaries can engage in dialogue, learn from one another, and find common ground through shared values of sportsmanship and respect. "The Olympics is a powerful testament to how people from diverse cultures and backgrounds can come together to achieve greatness," stated Nathan Kadisha, a K3 Principal. "The actions of Olympic athletes in Paris show us that dedication, perseverance, and mutual respect transcend borders and ideologies. These are the values that can truly unite us and drive real change beyond the games." “We are excited that Los Angeles will be hosting the Olympics four years from now,” Michael Kadisha said. “By watching athletes from rival nations compete with honor and integrity, in our own community, we will once again be reminded that even in competition, there is room for cooperation, empathy, and the possibility of resolving conflicts peacefully.” ### For more information or to schedule an interview with a K3 spokesperson, please contact Dan Rene at 202-329-8357 or dan@danrene.com Contact Details K3 Holdings/Alpine LA Properties Dan Rene +1 202-329-8357 dan@danrene.com Company Website https://k3holdings.com/

August 12, 2024 11:30 AM Eastern Daylight Time

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder

MarketJar

Major Depressive Disorder (MDD) was the third leading cause of global disease burden in 2008, according to the World Health Organization, with projections that it could become the leading cause by 2030. MDD is a severe mental health condition marked by persistent sadness, loss of interest in activities, and difficulties in daily functioning. 1 Lithium, a well-known mood stabilizer, has been used off-label for MDD, but its application is limited by safety concerns due to its narrow therapeutic window. In response to this unmet need, Alzamend Neuro, Inc. (NASDAQ:ALZN), a clinical-stage biopharmaceutical company, is dedicated to developing innovative treatments for neurological and psychiatric disorders, including MDD. The company's latest effort involves a promising partnership with Massachusetts General Hospital (MGH) to conduct a Phase II clinical trial of AL001, a next-generation lithium-based therapeutic candidate aimed at improving the safety and effectiveness of lithium treatment for MDD. Dr. Ovidiu Andronesi, an Associate Professor of Radiology at Harvard University, will lead the study. This trial aims to compare AL001's effectiveness and safety against a marketed lithium carbonate product by examining lithium levels in the brain and its structures. Alzamend Neuro, Inc. (NASDAQ:ALZN) previously completed a Phase IIA trial that identified a maximum tolerated dose (MTD) for AL001. This dose is designed to provide lithium at a safe and effective level without the need for frequent monitoring, unlike current lithium treatments that are limited by chronic toxicity and poor physicochemical properties. The primary goal of this study is to determine the ideal dose of AL001 that can achieve similar or better effectiveness and safety compared to existing lithium salts. Alzamend is optimistic that the study will meet regulatory safety standards through the FDA's Section 505(b)(2) pathway, which allows for new formulations of approved drugs. Stephan Jackman, Chief Executive Officer of Alzamend Neuro, Inc. (NASDAQ:ALZN), expressed enthusiasm about the partnership with Massachusetts General Hospital and Dr. Andronesi for the pivotal study of AL001. He highlighted the potential of AL001 to be a next-generation lithium product with an improved safety profile and enhanced brain biodistribution, which could eliminate the need for routine therapeutic drug monitoring (TDM). Jackman emphasized that developing such a product would represent a significant advancement over existing lithium-based treatments and could have a positive impact on the over 21 million Americans affected by Major Depressive Disorder (MDD). Alzamend plans to share more details about the study’s timeline and market opportunities in the near future. Alzamend Neuro and Massachusetts General Hospital Launch Phase II Trials of AL001 for Bipolar Disorder and Alzheimer’s Alzamend Neuro, Inc. (NASDAQ:ALZN) is also partnering with MGH to conduct Phase II clinical trials of AL001 for patients with bipolar disorder (BD) and Alzheimer’s disease. These trials are also led by Dr. Ovidiu Andronesi, an Associate Professor of Radiology at Harvard University. Lithium, the first mood stabilizer approved by the U.S. Food and Drug Administration (FDA), remains the gold standard for treating bipolar disorder (BD). With over 35 years of use, its safety profile is well established, which may reduce regulatory hurdles. This trial aims to compare the increase in brain lithium levels between AL001 and a commonly marketed lithium salt in BD patients, seeking to optimize dosing for enhanced effectiveness and safety. As for the Alzheimer’s trial, a cohort of healthy subjects will be studied to compare their plasma and brain pharmacokinetics with those of Alzheimer's patients. This trial aims to evaluate the increase in brain lithium levels and its distribution between AL001 and a commonly marketed lithium salt in both Alzheimer's patients and healthy subjects. Alzamend Neuro Secures $25 Million Funding to Advance Clinical Trials Alzamend Neuro, Inc. (NASDAQ:ALZN) recently secured the initial two tranches under a $25 million purchase agreement. This investment will drive the progress of Alzamend 's clinical trials and the development of next-generation treatments for Alzheimer’s, bipolar disorder, MDD, and PTSD. CEO Stephan Jackman highlighted the company’s commitment to achieving clinical milestones and transforming lithium-based therapies for millions of people affected by these conditions. Click here for more information about Alzamend Neuro, Inc. (NASDAQ:ALZN). [1] https://www.ncbi.nlm.nih.gov/books/NBK559078/ Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Alzamend Neuro, Inc. Market Jar Media Inc. was paid $1,500 for the production and publishing of this article by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.’s engagement by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-alzn. 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.’s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management’s expectations regarding Alzamend Neuro, Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Alzamend Neuro, Inc.’s industry; (b) market opportunity; (c) Alzamend Neuro, Inc.’s business plans and strategies; (d) services that Alzamend Neuro, Inc. intends to offer; (e) Alzamend Neuro, Inc.’s milestone projections and targets; (f) Alzamend Neuro, Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Alzamend Neuro, Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Alzamend Neuro, Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Alzamend Neuro, Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Alzamend Neuro, Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Alzamend Neuro, Inc.’s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) Alzamend Neuro, Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Alzamend Neuro, Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Alzamend Neuro, Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Alzamend Neuro, Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Alzamend Neuro, Inc.’s business operations (e) Alzamend Neuro, Inc. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Alzamend Neuro, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Alzamend Neuro, Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Alzamend Neuro, Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Alzamend Neuro, Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Alzamend Neuro, Inc. or such entities and are not necessarily indicative of future performance of Alzamend Neuro, Inc. or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on pressreach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

August 12, 2024 09:30 AM Eastern Daylight Time

Image

Therma Bright Inc. (OTCQB: TBRIF) (TSXV: THRM): Pioneering Growth in the Expanding Medical Devices Market

TBRIF

The medical device industry is expanding rapidly, propelled by technological advancements and rising healthcare demands around the world. The global medical devices market is on a growth trajectory, with a projected annual increase of 5.71%, reaching $673.10 billion by 2029, as reported by Statista. This expansion is largely driven by key markets like the United States, which is expected to generate $179.80 billion in medical device revenues in 2024 alone. In this expanding market, one company gaining attention is Therma Bright Inc. (OTCQB: TBRIF) (TSXV: THRM), a developer and partner in cutting-edge diagnostic and medical device technologies. Key Achievements and Market Positioning On July 3, 2024, Therma Bright provided a significant market update, underscoring major milestones achieved in Q2. A critical development was the successful securing of CAD $1,000,000 through a private placement, demonstrating strong investor confidence. These funds are allocated towards developing the Digital Cough Analyzer (DCA) and increasing the company’s stake in InStatin Inc., reflecting strategic moves across multiple high-growth markets. Therma Bright’s CEO, Rob Fia, highlighted that the proceeds would also support investor relations efforts and general working capital, emphasizing the company’s robust outlook. Venowave VW5: FDA Approval and Anticipated CPT/HCPCS Codes A major milestone for TBRIF in Q2 was the FDA’s approval of its 510K application for the Venowave VW5, a medical compression device designed to improve circulation in the lower extremities. This approval is pivotal as it meets the U.S. Centers for Medicare and Medicaid Services (CMS) requirement for issuing permanent CPT and HCPCS codes. The Venowave VW5 is a lightweight, discreet device that addresses circulatory issues such as deep vein thrombosis (DVT) and post-thrombotic syndrome (PTS). The market for DVT treatments alone is estimated to reach USD $1.554 billion by 2032, making this approval a significant achievement for Therma Bright. “With the FDA 510K application approval and CMS code designation recommendations complete, we anticipate the Venowave’s permanent codes approval imminently,” said Fia. “Our distribution partners are ready to deploy the Venowave to Medicare and Medicaid medical practitioners, offering an effective solution for patients suffering from various circulatory issues.” Awaiting CMS Approval: A Key Growth Catalyst As of August 1, 2024, Therma Bright received positive notification from CMS regarding the pending permanent CPT and HCPCS codes for its Venowave VW5 device. These codes are expected to cover ten critical health-related indications, from DVT prevention to enhancing blood circulation. The confirmation of these codes, anticipated in the coming days, will enable Therma Bright to fully leverage insurance reimbursements, significantly expanding its market reach. “We’re patiently awaiting confirmation from CMS, which is expected in a matter of days,” said Fia. “The approval of these permanent codes will be a game-changer for our distribution strategy and market penetration.” The confirmation of these codes is a pivotal opportunity for TBRIF because it allows the Venowave VW5 to be covered by insurance, making it more accessible to patients and more attractive to healthcare providers. This expansion into the insured market can significantly boost sales, revenue, and market presence, positioning Therma Bright as a leader in the circulatory health market. Digital Cough Analyzer (DCA) Powered by AI4LYF Therma Bright’s advancements are not limited to circulatory health. The company is also progressing with its AI-powered Digital Cough Analyzer (DCA). Positioned as a remote therapeutic monitoring solution, the DCA is poised to tap into the growing global respiratory monitoring market, which is expected to nearly double, reaching USD $2.99 billion by 2032. Plans are in place to work closely with the FDA on regulatory requirements, positioning the DCA as a key player in respiratory health technology. Strategic Investments in InStatin and Inretio TBRIF continues to enhance its portfolio through strategic investments in companies developing cutting-edge solutions in chronic lung disease management and ischemic stroke treatment. The company’s significant stakes in InStatin Inc. and Inretio are particularly noteworthy. The global markets for asthma treatment and coronary stents are projected to reach USD $30.1 billion and USD $4.8 billion by 2030 and 2029, respectively, highlighting the potential impact of these investments. Fia expressed optimism about these ventures, noting that InStatin’s innovative solution for chronic lung conditions, including asthma and COPD, could deliver substantial returns for shareholders. Conclusion Therma Bright Inc. (OTCQB: TBRIF) (TSXV: THRM) stands at an important moment in the medical device industry, with its innovative approaches positioning it for potential growth. The company’s advancements, including the anticipated CMS code approvals for the Venowave VW5, underscore its ability to capitalize on opportunities. By securing key regulatory approvals and investing in cutting-edge technologies, Therma Bright is not only enhancing its market presence but also setting the stage for transformative success. As the company continues to lead with solutions in circulatory health and respiratory monitoring, it presents an interesting investment opportunity. Savvy investors may want to closely monitor Therma Bright’s progress as it navigates this dynamic sector and drives forward with its ambitious growth strategy. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and expects to be compensated by Therma Brite to assist in the production and distribution of content related to TBRIF. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website https://razorpitch.com/

August 12, 2024 06:00 AM Eastern Daylight Time

NEC Bio Therapeutics and AGC Biologics Announce Collaboration to Manufacture Personalized Cancer Vaccines

AGC Biologics

NEC Bio Therapeutics and AGC Biologics have announced a partnership to advance the production of NECVAX-NEO1, an orally delivered, bacteria-based DNA vaccine designed to target patient-specific tumor neoantigens. This important and promising collaboration aims to enhance the production of personalized cancer treatments by leveraging the biotechnology strengths of both companies. Advancing Personalized Cancer Treatment NEC Bio Therapeutics, a Mannheim based German company focused on clinical development of innovative drugs by using proprietary AI, is developing NECVAX-NEO1, a personalized cancer vaccine that uses cutting-edge AI/machine learning technology to target specific tumor neoantigens that are unique to each patient. NECVAX-NEO1 relies on powerful and flexible plug-and-play bacteria-based platform technology and is convenient for patients due to its oral delivery. Unlike traditional treatments, NECVAX-NEO1 requires tailored manufacturing capacities and is produced by cost-efficient microbial fermentation at a small scale and with a quick turnaround time. New Phase1/2 clinical trials for NECVAX-NEO1 are slated to begin in cancer patients throughout 2024 and 2025. These trials will play a crucial role in validating the efficacy and safety of this novel treatment, potentially offering new hope to countless individuals battling cancer. Expert CDMO Collaboration for Global Manufacturing AGC Biologics is well-equipped to support the current supply chain needs of NECVAX-NEO1, ensuring timely delivery for clinical trials. As a global Contract Development and Manufacturing Organization (CDMO), AGC Biologics will use its state-of-the-art Heidelberg, Germany facility, a site with almost 40 years of microbial fermentation expertise, to perform a technology knowledge transfer, implementation and qualification of analytical methods, preparation for large scale clinical manufacturing, engineering and batch execution with Good Manufacturing Practices (GMP), and drug product release testing. "Personalized medicines have the potential to innovate how a treatment can address specific traits of a disease in a patient and give them a better quality of life. That is truly a remarkable endeavor, and the Heidelberg site is proud to have this opportunity to help NEC Bio Therapeutics on its mission of combining AI and machine learning with traditional biologics and personalized care,” said Dieter Kramer, General Manager, AGC Biologics Heidelberg. “We are eager to begin work and to collaborate with our new partners on this important journey.” AGC Biologics is the large molecule arm of the AGC Life Science Company, the life science division of AGC Inc. AGC Biologics offers end-to-end services for protein biologics, cell and gene therapies, plasmid DNA and messenger RNA, with operations in Europe, North America, and Japan. Collaboration Kickoff in Germany The partnership between NEC Bio Therapeutics and AGC Biologics will commence with a focus on clinical development and GMP-compliant manufacturing in Germany. Both companies have strategically positioned teams in Heidelberg and Mannheim, close to each other, fostering a collaborative environment for advancing this critical initiative. “We are thrilled to announce our collaboration with AGC Biologics to support the manufacturing of NECVAX-NEO1. This partnership represents a significant milestone in our commitment to delivering high-quality, affordable personalized cancer vaccines to patients. This collaboration underscores our dedication to improving global health outcomes in the oncology field. We look forward to the transformative impact this partnership will have on our operations and, more importantly, on the lives of the patients we serve," said Dr. Heinz Lubenau, CEO, NEC Bio Therapeutics. About NEC Bio Therapeutics NEC Bio Therapeutics, established in Manheim, Germany, focuses on the clinical strategy and development, as well as planning and execution of clinical trials in the oncology area. It is a subsidiary of NEC Bio, the biotech arm of NEC Corporation. NEC Bio, a subsidiary of NEC Corporation, is located in the Netherlands and dedicated to the development of innovative biotechnological solutions to tackle some of the most pressing health challenges. NEC Bio's research and development efforts are focused on creating personalized therapies that improve the quality of life for patients worldwide. NEC OncoImmunity in Oslo, Norway, is also a subsidiary of NEC Bio. For more information, visit NEC Bio: AI Drug Development | NEC. NEC is a registered trademark of NEC Corporation. All Rights Reserved. Other product or service marks mentioned herein are the trademarks of their respective owners. ©2024 NEC Corporation. About AGC Biologics: AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan. We currently employ more than 2,500 Team Members worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is a part of AGC Inc.’s Life Science Company. The Life Science company runs more than 10 global facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com. Contact Details Nick McDonald +1 425-419-3555 nmcdonald@agcbio.com Company Website https://www.agcbio.com/

August 07, 2024 10:13 PM Eastern Daylight Time

Benchmark International Successfully Facilitated the Transaction Between Pinnacle Fire Systems, Inc. and The Hiller Companies, LLC

Benchmark International

Benchmark International has successfully facilitated a transaction between Apex, NC-based Pinnacle Fire Systems, Inc. (“Pinnacle”) and The Hiller Companies (“Hiller”) of Mobile, AL. Pinnacle provides fire systems solutions to commercial and industrial customers in the Southeast United States. Pinnacle Fire Systems, Inc. was founded in 2001 to provide alarm safety solutions in and around the Raleigh/Durham area. The company provides total fire protection from start to finish within commercial buildings. Pinnacle installs, inspects, and maintains fire alarm and detection systems for commercial, health-care, and multifamily buildings. You built a great company; now build a great exit plan. The Hiller Companies offers fire protection and life safety products and services that preserve lives and property worldwide. Headquartered in Mobile, Alabama, Hiller extends its reach globally and in domestic markets with offices across the United States. The company is committed to being responsible stewards of the people, assets, and influence to ensure the safety and protection of the world. “Pinnacle’s owners, Rick Shores and Bart Arthurs, came to Benchmark International after having built a great company in a consolidating segment but were unsure of what valuation to seek from the market. Benchmark International's strong transactional history in the sector allowed us to achieve an outcome well over initial client expectations. We believe that Hiller is the perfect home for this great business, and we’re exceedingly happy with the result for our great founder team.” - William Sullivan, Senior Transaction Director, Benchmark International SCHEDULE A CALL! Americas: Sam Smoot at +1 (813) 898 2350/ Smoot@BenchmarkIntl.com Europe: Michael Lawrie at +44 (0) 161 359 4400 / Lawrie@BenchmarkIntl.com Africa: Anthony McCardle at +27 21 300 2055 / McCardle@BenchmarkIntl.com ABOUT BENCHMARK INTERNATIONAL: Benchmark International is a global M&A firm that provides business owners with creative, value-maximizing solutions for growing and exiting their businesses. Benchmark International has handled over $11 billion in transaction value across various industries from offices across the world. With decades of M&A experience, Benchmark International’s transaction teams have assisted business owners with achieving their objectives and ensuring the continued growth of their businesses. The firm has also been named the Investment Banking Firm of the Year by The M&A Advisor and the Global M&A Network as well as the #1 Sell-side Exclusive Privately-held M&A Advisor in the World by Pitchbook and Refinitiv's Global League Tables. Contact Details Brittney Zoeller +1 813-898-2350 zoeller@benchmarkintl.com Company Website https://www.benchmarkintl.com/

August 07, 2024 09:00 AM Eastern Daylight Time

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease

MarketJar

Mental health issues are on the rise, affecting almost 60 million US adults and more than 970 million people worldwide. 1 Rising cases has led to an uptick in new treatments moving through the clinical stages, including Alzamend Neuro, Inc. (NASDAQ:ALZN), which is focused on developing next-generation treatments for Alzheimer’s disease, bipolar disorder (BD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). Among its promising pipeline, AL001 stands out as a potential game-changer for bipolar disorder treatment. Alzamend Neuro 's AL001, a patented ionic cocrystal technology, aims to deliver lithium in a way that reduces toxicity while maintaining therapeutic efficacy by combining lithium, salicylate, and L-proline. Alzamend Neuro is rapidly advancing treatments for mental health disorders, potentially accelerating clinical phase progress due to the successes of AL001 in a Phase I and Phase IIA clinical trials for the treatment of Alzheimer’s. In 2023, the company filed IND applications for Phase IIA Clinical Trials of AL001 for Bipolar Disorder, MDD and PTSD. By the end of 2023, the FDA granted approval for these studies via “Study may proceed” letters. Alzamend Neuro Partners with MGH for Phase II Trial of Next-Generation Lithium Therapeutic Drug Candidate for Bipolar Disorder On August 6th, Alzamend Neuro, Inc. (NASDAQ:ALZN) announced a partnership with Massachusetts General Hospital (MGH) to conduct a Phase II clinical trial of AL001 for treatment of patients with bipolar disorder. MGH, the primary clinical education and research facility of Harvard Medical School, is the world's largest hospital-based research program. Dr. Ovidiu Andronesi MD, PhD, Associate Professor of Radiology at Harvard University and Director of Multinuclear Metabolic Imaging at the Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, will lead the study as the Principal Investigator. The trial will compare AL001 to a marketed lithium carbonate product, focusing on bioavailability and brain distribution of lithium, with the goal of establishing AL001's safe, effective, and tolerable dosing requirements. AL001 is designed to offer the therapeutic benefits of traditional lithium salts while minimizing their toxic side effects. This head-to-head study will measure lithium levels in the brain and structures of bipolar disorder patients, building on mouse studies that suggest AL001 can achieve therapeutic benefits at lower doses. The study will also leverage brain imaging to predict the efficacy and safety of AL001 compared to existing lithium treatments. Alzamend Neuro 's previous Phase IIA studies of AL001 in Alzheimer's patients and healthy subjects have demonstrated a benign safety profile, identifying a candidate dose unlikely to require therapeutic drug monitoring (TDM). This is a significant advancement, as current lithium treatments require rigorous monitoring due to their narrow therapeutic window and potential toxicity. “We are elated to partner with Massachusetts General Hospital and Dr. Andronesi in this pivotal study for our lead therapeutic candidate AL001,” said Alzamend Neuro, Inc. (NASDAQ:ALZN) CEO Stephan Jackman, “If we can develop a next-generation lithium product (AL001) with an improved safety profile and enhanced biodistribution in the brain that would not routinely require therapeutic drug monitoring (TDM), it would constitute a major improvement over current lithium-based treatments and positively impact the 7+ million Americans afflicted with bipolar disorder. We look forward to providing more details regarding study timelines and market opportunity in the near future.” This innovation has the potential to positively impact the over 7 million Americans living with bipolar disorder. Further details about the study timelines and market potential will be shared soon. Alzamend Neuro to Conduct a Phase II Clinical Trial of AL001, involving Patients with Alzheimer’s Disease Alzamend Neuro, Inc. (NASDAQ:ALZN) also just announced a collaboration with Massachusetts General Hospital (MGH) to conduct A Phase II clinical trial for AL001, for the potential treatment of Alzheimer's disease. This trial will involve both Alzheimer’s patients and healthy subjects to compare the bioavailability and brain distribution of AL001 versus a marketed lithium carbonate product. The trial, which will also be led by Dr. Ovidiu Andronesi of Harvard University, aim to establish AL001's safe, effective, and tolerable dosing requirements. The potential to avoid the need for therapeutic drug monitoring (TDM) is also significant, as it could simplify treatment regimens and improve patient compliance. By potentially offering a safer and more effective alternative to traditional lithium treatments, AL001 could revolutionize how Alzheimer's disease is managed. The ability to measure lithium levels directly in the brain and brain structures using advanced imaging techniques will provide invaluable insights into the drug’s efficacy and safety. This approach not only enhances our understanding of how AL001 works but also supports its potential approval through a Section 505(b)(2) pathway with the FDA. If successful, the trial could pave the way for a new era in Alzheimer's treatment, providing hope for millions of patients and their families. Financial Support for Clinical Trial In addition to this groundbreaking partnership, Alzamend Neuro, Inc. (NASDAQ:ALZN) recently secured the first two tranches of a $25 million Series A purchasing agreement. This investment supports the advancement of Alzamend 's clinical trial and the development of next-generation treatments for Alzheimer’s, bipolar disorder, MDD, and PTSD. CEO Stephan Jackman emphasized the company's dedication to advancing clinical milestones and revolutionizing lithium-based therapies for millions affected by these conditions. Click here for more information about Alzamend Neuro, Inc. (NASDAQ:ALZN). [1] https://www.who.int/health-topics/mental-health#tab=tab_2 Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Alzamend Neuro, Inc. Market Jar Media Inc. was paid $1,500 for the production and publishing of this article by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.’s engagement by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-alzn. 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Alzamend Neuro, Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Alzamend Neuro, Inc.’s industry; (b) market opportunity; (c) Alzamend Neuro, Inc.’s business plans and strategies; (d) services that Alzamend Neuro, Inc. intends to offer; (e) Alzamend Neuro, Inc.’s milestone projections and targets; (f) Alzamend Neuro, Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Alzamend Neuro, Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Alzamend Neuro, Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Alzamend Neuro, Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Alzamend Neuro, Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Alzamend Neuro, Inc.’s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) Alzamend Neuro, Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Alzamend Neuro, Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Alzamend Neuro, Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Alzamend Neuro, Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Alzamend Neuro, Inc.’s business operations (e) Alzamend Neuro, Inc. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Alzamend Neuro, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Alzamend Neuro, Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Alzamend Neuro, Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Alzamend Neuro, Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Alzamend Neuro, Inc. or such entities and are not necessarily indicative of future performance of Alzamend Neuro, Inc. or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on pressreach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

August 06, 2024 11:45 AM Eastern Daylight Time

Image

Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology

Benzinga

By Meg Flippin, Benzinga Citius Pharmaceuticals Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company, is progressing with its focus on unlocking value for investors by announcing that shareholders of TenX Keane Acquisition (NASDAQ: TENK), a publicly traded special purpose acquisition company, have voted to approve the previously announced business combination between TenX Keane and Citius Pharma’s oncology subsidiary. The newly combined public company will continue to trade on the Nasdaq stock exchange and is to be renamed Citius Oncology, Inc. In October, Citius announced it was spinning out its wholly-owned oncology unit to form Citius Oncology, a standalone publicly traded entity. Under the terms of the deal, Citius Pharma is getting 65.6 million shares of common stock of Citius Oncology, which would represent approximately 90% of the newly public company. As part of the transaction, Citius Pharma will contribute $10 million in cash to Citius Oncology. An additional 12.75 million existing options will be assumed by Citius Oncology. At closing, any cash remaining in TenX’s trust account along with the cash provided by Citius Pharma will be contributed to Citius Oncology for working capital and general corporate purposes of Citius Oncology following the transaction. Unlocking Significant Value Citius previously stated that the SPAC deal is expected to unlock significant value for Citius shareholders by separating the oncology business, potentially leading to increased access to capital markets and further development of new applications and additional intellectual property. It also underscores Citius’ strategy to purchase assets, develop them and bring them to market and then unlock shareholder value. First Out Of The Gate: LYMPHIR Citius Oncology will serve as a platform to develop and commercialize novel targeted oncology therapies. The first to go to market will be LYMPHIR, a recombinant fusion protein designed to treat T-cell lymphomas. Citius said the deal is expected to provide Citius Oncology with improved access to the public equity markets and thereby facilitate the commercialization of LYMPHIR and position the company to explore additional value-creating opportunities more fully. The drug agent LYMPHIR combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. In 2011 and 2013, the FDA granted orphan drug designation to LYMPHIR for the treatment of peripheral T-cell lymphoma (PTCL) and Cutaneous T-cell lymphoma (CTCL). In 2021, Citius acquired an exclusive license with rights to develop and commercialize LYMPHIR in all markets except for Japan and certain other parts of Asia. In March this year, the FDA accepted Citius’s Biologics License Application (BLA) for LYMPHIR with a decision expected on August 13, 2024, the FDA's assigned Prescription Drug User Fee Act (PDUFA) action date. If approved, Citius is preparing for LYMPHIR commercialization later this year. “The reason we are doing this is acquire a Nasdaq listing by having the SPAC acquire the assets and at the same time it enables us to do something to prevent dilution for shareholders,” said Leonard Mazur, CEO of Citius in a recent interview with Benzinga. The CEO counts himself as one of the shareholders. He has invested $22.5 million of his own money in the business. “During the first year on the market we will be profitable. All that benefits Citius shareholders,” he said. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 06, 2024 10:45 AM Eastern Daylight Time

Image

Headline

MarketJar

Mental health issues are on the rise, affecting almost 60 million US adults and more than 970 million people worldwide. 1 Rising cases has led to an uptick in new treatments moving through the clinical stages, including Alzamend Neuro, Inc. (NASDAQ:ALZN), which is focused on developing next-generation treatments for Alzheimer’s disease, bipolar disorder (BD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). Among its promising pipeline, AL001 stands out as a potential game-changer for bipolar disorder treatment. Alzamend Neuro 's AL001, a patented ionic cocrystal technology, aims to deliver lithium in a way that reduces toxicity while maintaining therapeutic efficacy by combining lithium, salicylate, and L-proline. Alzamend Neuro is rapidly advancing treatments for mental health disorders, potentially accelerating clinical phase progress due to the successes of AL001 in a Phase I and Phase IIA clinical trials for the treatment of Alzheimer’s. In 2023, the company filed IND applications for Phase IIA Clinical Trials of AL001 for Bipolar Disorder, MDD and PTSD. By the end of 2023, the FDA granted approval for these studies via “Study may proceed” letters. Alzamend Neuro Partners with MGH for Phase II Trial of Next-Generation Lithium Therapeutic Drug Candidate for Bipolar Disorder On August 6th, Alzamend Neuro, Inc. (NASDAQ:ALZN) announced a partnership with Massachusetts General Hospital (MGH) to conduct a Phase II clinical trial of AL001 for treatment of patients with bipolar disorder. MGH, the primary clinical education and research facility of Harvard Medical School, is the world's largest hospital-based research program. Dr. Ovidiu Andronesi MD, PhD, Associate Professor of Radiology at Harvard University and Director of Multinuclear Metabolic Imaging at the Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, will lead the study as the Principal Investigator. The trial will compare AL001 to a marketed lithium carbonate product, focusing on bioavailability and brain distribution of lithium, with the goal of establishing AL001's safe, effective, and tolerable dosing requirements. AL001 is designed to offer the therapeutic benefits of traditional lithium salts while minimizing their toxic side effects. This head-to-head study will measure lithium levels in the brain and structures of bipolar disorder patients, building on mouse studies that suggest AL001 can achieve therapeutic benefits at lower doses. The study will also leverage brain imaging to predict the efficacy and safety of AL001 compared to existing lithium treatments. Alzamend Neuro 's previous Phase IIA studies of AL001 in Alzheimer's patients and healthy subjects have demonstrated a benign safety profile, identifying a candidate dose unlikely to require therapeutic drug monitoring (TDM). This is a significant advancement, as current lithium treatments require rigorous monitoring due to their narrow therapeutic window and potential toxicity. “We are elated to partner with Massachusetts General Hospital and Dr. Andronesi in this pivotal study for our lead therapeutic candidate AL001,” said Alzamend Neuro, Inc. (NASDAQ:ALZN) CEO Stephan Jackman, “If we can develop a next-generation lithium product (AL001) with an improved safety profile and enhanced biodistribution in the brain that would not routinely require therapeutic drug monitoring (TDM), it would constitute a major improvement over current lithium-based treatments and positively impact the 7+ million Americans afflicted with bipolar disorder. We look forward to providing more details regarding study timelines and market opportunity in the near future.” This innovation has the potential to positively impact the over 7 million Americans living with bipolar disorder. Further details about the study timelines and market potential will be shared soon. Alzamend Neuro to Conduct a Phase II Clinical Trial of AL001, involving Patients with Alzheimer’s Disease Alzamend Neuro, Inc. (NASDAQ:ALZN) also just announced a collaboration with Massachusetts General Hospital (MGH) to conduct A Phase II clinical trial for AL001, for the potential treatment of Alzheimer's disease. This trial will involve both Alzheimer’s patients and healthy subjects to compare the bioavailability and brain distribution of AL001 versus a marketed lithium carbonate product. The trial, which will also be led by Dr. Ovidiu Andronesi of Harvard University, aim to establish AL001's safe, effective, and tolerable dosing requirements. The potential to avoid the need for therapeutic drug monitoring (TDM) is also significant, as it could simplify treatment regimens and improve patient compliance. By potentially offering a safer and more effective alternative to traditional lithium treatments, AL001 could revolutionize how Alzheimer's disease is managed. The ability to measure lithium levels directly in the brain and brain structures using advanced imaging techniques will provide invaluable insights into the drug’s efficacy and safety. This approach not only enhances our understanding of how AL001 works but also supports its potential approval through a Section 505(b)(2) pathway with the FDA. If successful, the trial could pave the way for a new era in Alzheimer's treatment, providing hope for millions of patients and their families. Financial Support for Clinical Trial In addition to this groundbreaking partnership, Alzamend Neuro, Inc. (NASDAQ:ALZN) recently secured the first two tranches of a $25 million Series A purchasing agreement. This investment supports the advancement of Alzamend 's clinical trial and the development of next-generation treatments for Alzheimer’s, bipolar disorder, MDD, and PTSD. CEO Stephan Jackman emphasized the company's dedication to advancing clinical milestones and revolutionizing lithium-based therapies for millions affected by these conditions. Click here for more information about Alzamend Neuro, Inc. (NASDAQ:ALZN). [1] https://www.who.int/health-topics/mental-health#tab=tab_2 Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Alzamend Neuro, Inc. Market Jar Media Inc. was paid $1,500 for the production and publishing of this article by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.’s engagement by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-alzn. 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Alzamend Neuro, Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Alzamend Neuro, Inc.’s industry; (b) market opportunity; (c) Alzamend Neuro, Inc.’s business plans and strategies; (d) services that Alzamend Neuro, Inc. intends to offer; (e) Alzamend Neuro, Inc.’s milestone projections and targets; (f) Alzamend Neuro, Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Alzamend Neuro, Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Alzamend Neuro, Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Alzamend Neuro, Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Alzamend Neuro, Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Alzamend Neuro, Inc.’s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) Alzamend Neuro, Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Alzamend Neuro, Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Alzamend Neuro, Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Alzamend Neuro, Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Alzamend Neuro, Inc.’s business operations (e) Alzamend Neuro, Inc. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Alzamend Neuro, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Alzamend Neuro, Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Alzamend Neuro, Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Alzamend Neuro, Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Alzamend Neuro, Inc. or such entities and are not necessarily indicative of future performance of Alzamend Neuro, Inc. or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on pressreach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

August 06, 2024 09:00 AM Eastern Daylight Time

Image

HPS/PayMedix Acquires TempoPay to Further Expand and Simplify Healthcare Payments for All

HPS|PayMedix

HPS/PayMedix today announced the acquisition of TempoPay, an innovative payments solution created at Redesign Health that helps employees access medical, dental, pharmacy, and other expenses not paid by their insurance. Together, HPS/PayMedix and TempoPay now offer a comprehensive healthcare financing and payments solution, addressing the issues of health equity, affordability, and the need to simplify the healthcare payments experience. According to the PayMedix Healthcare Payments and Financial Disparities Study, one-third of Americans say out-of-pocket costs (33%) and deductibles (31%) are unaffordable. This figure increases to four in ten for those with a credit score of 669 or less. Further, more than half (52%) of insured Americans said that paying for medical bills has been stressful, with nearly all of them (92%) claiming the stress has affected their physical and mental health. “Healthcare costs are increasingly becoming a disproportionate share of the American household wallet, and we need better solutions to manage the stress this puts on family budgets,” said Tom Policelli, CEO of HPS/PayMedix. “The acquisition of TempoPay underscores our mission to simplify healthcare and create greater health equity by removing the financial barriers that stand in the way of employees getting access to the care they need when they need it; not just when they feel that they can afford it.” TempoPay offers all an employer’s employees’ interest-free financing for health and wellbeing care that overlays their current plans. Once activated by the employee, TempoPay VISA® cards can be used to pay for everything from medical care and prescriptions to vision and dental bills; even vet bills for their pet and other approved health and wellness-related costs not covered by their plans. The employer sets the dollar amount and charge types that will be processed, and employees can repay their bills over time interest-free via payroll or bank account. “TempoPay is the lifeline employees need today so they can access care and maintain their health without fearing high interest bills or avoiding needed care,” Erika Davison-Aviles, CEO and Co-founder of TempoPay said. “We are excited to become a part of HPS/PayMedix’s innovative healthcare payment solution and further our mission to alleviate consumers’ financial pressure. For employers we help maximize the value of their benefits plans, pre-tax accounts, and other well-being programs.” With TempoPay and PayMedix combined, all employees can access interest-free financing for all their healthcare needs. While TempoPay offers immediate financing of everyday healthcare expenses, PayMedix provides complete, uncapped financing for all in-network allowed charges that any employee may owe to providers. All employees are automatically enrolled and PayMedix then pays all participating providers in full. The employees each get a simplified consolidated statement (a SuperEOB) each month and can arrange to pay it on terms that fit their budgets. Participating providers, in turn, are simply paid the full employee balance due automatically and therefore have no bill to collect. Because PayMedix and TempoPay are ‘credit-blind’, all employees, regardless their credit histories, can make their healthcare expenses more manageable. “It’s a fact that 1 in 4 PayMedix members would be unable to get financing for their healthcare based on their credit scores. With TempoPay, we can reach even more members to help them get and stay healthy,” said Brian Marsella, President of HPS/PayMedix. “The powerful combination of PayMedix and TempoPay provides employers with a valuable solution to support their workforce. We have proven that improving access to care drives better outcomes – particularly for lower-income employees. This in turn saves employers money.” About PayMedix PayMedix, which began as the financing arm of Wisconsin-based HPS over a decade ago, is the only company solving the problem of high out-of-pocket costs for everyone -- providers, patients, employers, and TPAs. PayMedix is changing how people access, use, and pay for healthcare by guaranteeing payments to providers and financing for all patients. PayMedix has processed more than $5 billion in medical payments for hospital systems and physician practices and can be implemented in conjunction with any PPO or HMO network. About TempoPay TempoPay partners with employers to help their employees manage their medical costs with interest-free financing and flexible repayment options. With theTempoPay Visa ® card employees can take control of how they pay for healthcare without added stress, providing simple access to the financial security needed for happier, healthier lives. About HPS Health Payment Systems (HPS) is a privately held healthcare technology and services organization with solutions that reduce the cost and complexity of the healthcare payments process to benefit providers, employers, patients and TPAs. Headquartered in Milwaukee, Wisconsin, HPS has an independent network of 100+ hospital facilities and 29,200+ individual providers. Contact Details Kaitlynn Cooney +1 609-351-5944 kcooney@brodeur.com Company Website https://paymedix.com

August 06, 2024 08:00 AM Eastern Daylight Time